Atypical hemolytic uremic syndrome in a patient with protein-losing enteropathy

被引:6
作者
Hanna, Ramy M. [1 ]
Hasnain, Huma [1 ]
Abdelnour, Lama [1 ]
Yanny, Beshoy [2 ]
Burwick, Richard M. [3 ]
机构
[1] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Nephrol, Room 7-155 Factor Bldg,700 Tiverton Ave, Los Angeles, CA 90095 USA
[2] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Digest Dis,Hepatol, Los Angeles, CA 90095 USA
[3] Cedars Sinai Med Ctr, Dept Obstet & Gynecol, Div Maternal Fetal Med, Los Angeles, CA 90048 USA
关键词
Atypical hemolytic uremic syndrome; thrombotic microangiopathy; hemolysis; protein-losing enteropathy; hypoalbuminemia; eculizumab; ECULIZUMAB; DISCONTINUATION;
D O I
10.1177/0300060519864808
中图分类号
R-3 [医学研究方法]; R3 [基础医学];
学科分类号
1001 ;
摘要
Atypical hemolytic uremic syndrome (aHUS) is an ultra-rare disease induced by many triggers, all of which produce a common end phenotype of microangiopathic hemolysis and thrombotic microangiopathy. We herein describe a 63-year-old woman with ongoing protein-losing enteropathy and frequent transudates caused by hypoalbuminemia. The patient was treated with eculizumab with a full hematologic and partial renal response. Protein-losing enteropathy is an inflammatory condition that has been linked with increased complement activation, which can trigger aHUS in patients with loss of CD55 expression. The patient in the present case had an increased estimated glomerular filtration rate but stage IV to V chronic kidney disease. One year later, she remains off dialysis with a stable estimated glomerular filtration rate. We herein report an unusual trigger of complement activation that in turn triggered aHUS in this patient.
引用
收藏
页码:4027 / 4032
页数:6
相关论文
共 17 条
  • [1] Discontinuation of Eculizumab Maintenance Treatment for Atypical Hemolytic Uremic Syndrome: A Report of 10 Cases
    Ardissino, Gianluigi
    Testa, Sara
    Possenti, Ilaria
    Tel, Francesca
    Paglialonga, Fabio
    Salardi, Stefania
    Tedeschi, Silvana
    Belingheri, Mirco
    Cugno, Massimo
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 2014, 64 (04) : 633 - 637
  • [2] Genetic Analysis of 400 Patients Refines Understanding and Implicates a New Gene in Atypical Hemolytic Uremic Syndrome
    Bu, Fengxiao
    Zhang, Yuzhou
    Wang, Kai
    Borsa, Nicolo Ghiringhelli
    Jones, Michael B.
    Taylor, Amanda O.
    Takanami, Erika
    Meyer, Nicole C.
    Frees, Kathy
    Thomas, Christie P.
    Nester, Carla
    Smith, Richard J. H.
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 29 (12): : 2809 - 2819
  • [3] Predictive Features of Severe Acquired ADAMTS13 Deficiency in Idiopathic Thrombotic Microangiopathies: The French TMA Reference Center Experience
    Coppo, Paul
    Schwarzinger, Michael
    Buffet, Marc
    Wynckel, Alain
    Clabault, Karine
    Presne, Claire
    Poullin, Pascale
    Malot, Sandrine
    Vanhille, Philippe
    Azoulay, Elie
    Galicier, Lionel
    Lemiale, Virginie
    Mira, Jean-Paul
    Ridel, Christophe
    Rondeau, Eric
    Pourrat, Jacques
    Girault, Stephane
    Bordessoule, Dominique
    Saheb, Samir
    Ramakers, Michel
    Hamidou, Mohamed
    Vernant, Jean-Paul
    Guidet, Bertrand
    Wolf, Martine
    Veyradier, Agnes
    [J]. PLOS ONE, 2010, 5 (04):
  • [4] Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation
    Fakhouri, Fadi
    Fila, Marc
    Provot, Francois
    Delmas, Yahsou
    Barbet, Christelle
    Chatelet, Valerie
    Rafat, Cedric
    Cailliez, Mathilde
    Hogan, Julien
    Servais, Aude
    Karras, Alexandre
    Makdassi, Raifah
    Louillet, Feriell
    Coindre, Jean-Philippe
    Rondeau, Eric
    Loirat, Chantal
    Fremeaux-Bacchi, Veronique
    [J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2017, 12 (01): : 50 - 59
  • [5] Complement in Thrombotic Microangiopathies: Unraveling Ariadne's Thread Into the Labyrinth of Complement Therapeutics
    Gavriilaki, Eleni
    Anagnostopoulos, Achilles
    Mastellos, Dimitrios C.
    [J]. FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [6] George JN, 2014, NEW ENGL J MED, V371, P1847, DOI [10.1056/NEJMc1410951, 10.1056/NEJMra1312353]
  • [7] Hanna RM, 2017, J ONCO NEPHROLOGY, V1, pe1, DOI [10.5301/jo-n.5000021, DOI 10.5301/J0-N.5000021]
  • [8] Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome
    Legendre, C. M.
    Licht, C.
    Muus, P.
    Greenbaum, L. A.
    Babu, S.
    Bedrosian, C.
    Bingham, C.
    Cohen, D. J.
    Delmas, Y.
    Douglas, K.
    Eitner, F.
    Feldkamp, T.
    Fouque, D.
    Furman, R. R.
    Gaber, O.
    Herthelius, M.
    Hourmant, M.
    Karpman, D.
    Lebranchu, Y.
    Mariat, C.
    Menne, J.
    Moulin, B.
    Nuernberger, J.
    Ogawa, M.
    Remuzzi, G.
    Richard, T.
    Sberro-Soussan, R.
    Severino, B.
    Sheerin, N. S.
    Trivelli, A.
    Zimmerhackl, L. B.
    Goodship, T.
    Loirat, C.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 368 (23) : 2169 - 2181
  • [9] Current evidence on the discontinuation of eculizumab in patients with atypical haemolytic uraemic syndrome
    Macia, Manuel
    de Alvaro Moreno, Fernando
    Dutt, Tina
    Fehrman, Ingela
    Hadaya, Karine
    Gasteyger, Christoph
    Heyne, Nils
    [J]. CLINICAL KIDNEY JOURNAL, 2017, 10 (03): : 310 - 319
  • [10] Compstatin: a C3-targeted complement inhibitor reaching its prime for bedside intervention
    Mastellos, Dimitrios C.
    Yancopoulou, Despina
    Kokkinos, Petros
    Huber-Lang, Markus
    Hajishengallis, George
    Biglarnia, Ali R.
    Lupu, Florea
    Nilsson, Bo
    Risitano, Antonio M.
    Ricklin, Daniel
    Lambris, John D.
    [J]. EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 2015, 45 (04) : 423 - 440